

**PRESCRIBED DRUGS IMMUNIZATION FEE SCHEDULE
COVERAGE INFORMATION AND SPECIAL CONSIDERATIONS**

General Immunization Billing Requirements:

Florida Medicaid providers administering vaccines to Florida Medicaid recipients enrolled in the fee-for-service delivery system must submit two Current Procedural Terminology (CPT) codes on the claim for reimbursement of administration from Florida Medicaid: (1)The vaccine product code AND (2)The vaccine administration code. A corresponding administration code must be submitted for each vaccine administered during the same visit on the claim form.

Vaccines for Children (VFC) Program Reimbursement Guidelines:

Florida Medicaid providers receiving vaccine products through the Vaccine for Children (VFC) Program for fee-for-service recipients 0 through 18 years of age are reimbursed for the administration of the vaccine(s) only. Vaccine product codes are reimbursed at \$0.00. Vaccine administration codes are reimbursed in accordance with rates established on this fee schedule.

MediKids Guidelines:

MediKids enrolls children one through four years of age. MediKids enrollees are eligible for all immunizations recommended by the Advisory Committee on Immunization Practices (ACIP) for this age group. However, MediKids enrollees are not eligible to receive products provided through the VFC Program. Florida Medicaid providers who administer vaccines to MediKids enrollees are to be reimbursed for the vaccine products and administration services by the enrollee's Managed Care Plan.

Mid-level Practitioner Reimbursement:

Administration services are reimbursed at 80% of the maximum fee when performed by an advanced practice registered nurse (APRN), physician's assistant (PA), or registered pharmacist (RPh). Vaccine product codes are reimbursed in accordance with rates established on this fee schedule.

COVID-19 Vaccine Billing and Reimbursement Guidelines:

Florida Medicaid providers administering COVID-19 vaccines to Florida Medicaid recipients enrolled in the fee-for-service delivery system must submit the CPT code for the specific vaccine product in conjunction with the COVID-19-specific vaccine administration code on the claim for reimbursement. The product CPT code and the COVID-19 administration code must be submitted for each vaccine dose administered on the claim form.

^ Respiratory Syncytial Virus monoclonal antibody codes have specific administration codes that must be billed together.

PRESCRIBED DRUGS IMMUNIZATION FEE SCHEDULE

EFFECTIVE: JANUARY 1, 2026 2025

| CPT Code | Modifier | Description | Units | Age (Years) | MaxFee |
|---|----------|---|-------|-------------|--------|
| GENERAL VACCINE ADMINISTRATION CODES | | | | | |
| 90460 | | Administration of first vaccine or toxoid component through 18 years of age, with counseling | | 0-18 | 10.00 |
| 90471 | | Administration of one vaccine, single or combination vaccine/toxoid. (percutaneous, intradermal, subcutaneous or intramuscular) | | 0-18 0+ | 10.00 |
| 90471 | HA | Administration of one vaccine, single or combination vaccine/toxoid. (percutaneous, intradermal, subcutaneous or intramuscular) | | 19+ | 10.00 |
| 90472 | | Administration of each additional vaccine, single or combination vaccine/toxoid. (percutaneous, intradermal, subcutaneous or intramuscular) | | 0-18 0+ | 10.00 |
| 90472 | HA | Administration of each additional vaccine, single or combination vaccine/toxoid. (percutaneous, intradermal, subcutaneous or intramuscular) | | 19+ | 10.00 |
| 90473 | | Immunization administration by intranasal or oral route of one vaccine, single or combination vaccine/toxoid. | | 0-18 0+ | 10.00 |
| 90473 | HA | Immunization administration by intranasal or oral route of one vaccine, single or combination vaccine/toxoid. | | 19+ | 10.00 |
| 90474 | | Administration of each additional intranasal or oral vaccine (single or combination vaccine/toxoid) | | 0-18 0+ | 10.00 |
| 90474 | HA | Administration of each additional intranasal or oral vaccine (single or combination vaccine/toxoid) | | 19+ | 10.00 |
| CHIKUNGUNYA | | | | | |
| 90589 | | Chikungunya virus vaccine, live attenuated, for intramuscular use [Ixchiq] | 1 | 18+ | 275.00 |

| PRESCRIBED DRUGS IMMUNIZATION FEE SCHEDULE | | | | | |
|--|----|--|---|---------|-------------------------|
| EFFECTIVE: JANUARY 1, 2026 2025 | | | | | |
| MPOX | | | | | |
| 90611 | | Smallpox and monkeypox vaccine, attenuated vaccinia virus, live, non-replicating, preservative free, 0.5 mL dosage, suspension, for subcutaneous use [<i>JYNNEOS</i>] | 1 | 18+ | <u>247.34</u> 270.00 |
| HEPATITIS B | | | | | |
| 90739 | | Hepatitis B vaccine (HepB), CpG-adjuvanted, adult dosage, 2 dose or 4 dose schedule for intramuscular use [<i>HEPLISAV-B</i>] | 1 | 18+ | <u>155.75</u> 147.63 |
| 90740 | | Hepatitis B vaccine (HepB), dialysis or immunosuppressed patient dosage, 3 dose schedule, for intramuscular use [<i>RECOMBIVAX-DIALYSIS</i>] | 1 | 18+ | <u>164.42</u> 158.15 |
| 90743 | | Hepatitis B vaccine (HepB), adolescent, 2 dose schedule, for intramuscular use [<i>RECOMBIVAX HB-ADULT</i>] | 1 | 11 - 15 | <u>72.21</u> 68.81 |
| 90744 | | Hepatitis B vaccine (HepB), pediatric/adolescent dosage, 3 dose schedule, for intramuscular use [<i>Recombivax-PEDS; Engerix-B-PEDS</i>] | 1 | 0-18 | 0.00 |
| 90746 | | Hepatitis B vaccine (HepB), adult dosage, 3 dose schedule for intramuscular use [<i>RECOMBIVAX HB-ADULT, ENERGIX-B ADULT</i>] | 1 | 19+ | <u>72.23</u> 68.81 |
| 90759 | | Hepatitis B vaccine (HepB), 3-antigen (S, Pre-S1, Pre-S2), 10 mcg dosage, 3 dose schedule, for intramuscular use [<i>PREHEVBRIO Hepatitis B Vaccine (Recombinant)</i>] | 1 | 18+ | 73.82 |
| ROTAVIRUS (RV) | | | | | |
| 90680 | | Rotavirus vaccine, pentavalent [RV5], 3 dose schedule, live, for oral use [<i>RotaTeq</i>] | 1 | 0-1 | 0.00 |
| 90681 | | Rotavirus vaccine, human, attenuated [RV1], 2 dose schedule, live, for oral use [<i>Rotarix</i>] | 1 | 0-1 | 0.00 |
| DIPHTHERIA/TETANUS/ACELLULAR PERTUSSIS AND COMBINATIONS | | | | | |
| Diphtheria, Tetanus, & Pertussis (DTaP) | | | | | |
| 90700 | | Diphtheria, tetanus, and acellular pertussis (whooping cough) (DTaP), intramuscular [<i>Daptacel; Infanrix</i>] | 1 | 0-6 | 0.00 |
| Diphtheria & Tetanus (DT) | | | | | |
| 90702 | | Diphtheria and tetanus toxoids, intramuscular [<i>DT</i>] | 1 | 0-7 | 0.00 |
| Tetanus & Diphtheria (Td) | | | | | |
| 90714 | | Tetanus and diphtheria toxoids, intramuscular [<i>Tenivac</i>] | 1 | 7 - 18 | 0.00 |
| 90714 | HA | Tetanus and diphtheria toxoids, intramuscular [<i>Tenivac</i>] | 1 | 19+ | <u>42.25</u> 37.10 |
| Tetanus, Diphtheria, & Pertussis (Tdap) | | | | | |
| 90715 | | Tetanus, diphtheria toxoids, and acellular pertussis (whooping cough) (Tdap), intramuscular [<i>Boostrix, Adacel</i>] | 1 | 7 - 18 | 0.00 |
| 90715 | HA | Tetanus, diphtheria toxoids, and acellular pertussis (whooping cough) (Tdap), intramuscular [<i>Boostrix, Adacel</i>] | 1 | 19+ | <u>48.98</u> 47.61 |
| Diphtheria & Tetanus Combinations | | | | | |
| 90696 | | Diphtheria, tetanus toxoids, acellular pertussis (whooping cough), and polio (DTaP-IPV), intramuscular [<i>Quadracel; Kinrix</i>] | 1 | 4 - 6 | 0.00 |
| 90697 | | Diphtheria, tetanus toxoids, acellular pertussis (whooping cough), polio, Haemophilus influenza type b and hepatitis B (DTaP-IPV-HIB-HEPB), intramuscular [<i>Vaxelis</i>] | 1 | 0-4 | 0.00 |
| 90698 | | Diphtheria, tetanus toxoids, acellular pertussis (whooping cough), Haemophilus influenza type B and polio (DTaP-HIB-IPV), intramuscular [<i>Pentacel</i>] | 1 | 0-4 | 0.00 |
| 90723 | | Diphtheria, tetanus toxoids, acellular pertussis (whooping cough), Hepatitis B, and polio (DTaP-HepB-IPV), intramuscular [<i>Pediarix - Latex Free</i>] | 1 | 0-6 | 0.00 |
| HAEMOPHILUS INFLUENZAE TYPE B (Hib) | | | | | |

| PRESCRIBED DRUGS IMMUNIZATION FEE SCHEDULE | | | | | |
|---|----|--|---|----------------------------|------------------------------------|
| EFFECTIVE: JANUARY 1, 2026 2025 | | | | | |
| 90647 | | Haemophilus influenzae B (3 dose schedule) injection into muscle [<i>PedvaxHIB</i>] | 1 | 0-5 | 0.00 |
| 90648 | | Haemophilus influenzae B (4 dose schedule) injection into muscle [<i>ActHIB; Hiberix</i>] | 1 | 0-5 | 0.00 |
| PNEUMOCOCCAL | | | | | |
| 90670 | | Pneumococcal conjugate 13 valent, intramuscular [<i>PREVNAR 13</i>] | ± | 0-18 | 257.99 |
| 90671 | | Pneumococcal Conjugate Vaccine 15 valent, intramuscular (PCV15) [<i>VAXNEUVANCE</i>] | 1 | 0-18 | 0.00 |
| 90671 | HA | Pneumococcal Conjugate Vaccine 15 valent, intramuscular (PCV15) [<i>VAXNEUVANCE</i>] | 1 | 19+ | <u>240.62</u> 229.20 |
| 90677 | | Pneumococcal Conjugate Vaccine 20 valent, intramuscular (PCV20) [<i>PREVNAR 20</i>] | 1 | 0-18 | 0.00 |
| 90677 | HA | Pneumococcal Conjugate Vaccine 20 valent, intramuscular (PCV20) [<i>PREVNAR 20</i>] | 1 | 19+ | <u>274.60</u> 261.56 |
| 90732 | | Pneumococcal polysaccharide 23 valent subcutaneous or intramuscular [<i>PNEUMOVAX 23</i>] | 1 | 2 - 18 | 0.00 |
| 90732 | HA | Pneumococcal polysaccharide 23 valent subcutaneous or intramuscular [<i>PNEUMOVAX 23</i>] | 1 | 19+ | 117.08 |
| 90684 | | Pneumococcal conjugate vaccine, 21 valent (PCV21), for intramuscular use [<i>CAPVAXIVE</i>] | 1 | 18+ | <u>302.10</u> 287.75 |
| INACTIVATED POLIOVIRUS (IPV) | | | | | |
| 90713 | | Polio vaccine, injection beneath the skin or into muscle [<i>IPOLE</i>] | 1 | 0-18 | 0.00 |
| 90713 | HA | Polio vaccine, injection beneath the skin or into muscle [<i>IPOLE</i>] | 1 | 19+ | <u>44.73</u> 42.64 |
| INFLUENZA, 2025 - 2026 2024 – 2025 SEASON | | | | | |
| Influenza (aIV) | | | | | |
| 90653 | | Influenza vaccine, inactivated (IIV), subunit, adjuvanted, for intramuscular use [<i>FLUAD</i>] | 1 | 18+ | <u>98.16</u> 83.49 |
| Influenza (IIV3) | | | | | |
| 90655 | | Influenza virus vaccine, trivalent (IIV3), split virus, preservative free, 0.25 mL dosage, for intramuscular use* | ± | 0-2 | 0.00 |
| 90656 | | Influenza virus vaccine, trivalent (IIV3), split virus, preservative free, 0.5 mL dosage, for intramuscular use [<i>FLULAVAL TIV, FLUZONE TIV</i>] | 1 | 0-18 | <u>0.00</u> 20.67 |
| 90656 | HA | Influenza virus vaccine, trivalent (IIV3), split virus, preservative free, 0.5 mL dosage, for intramuscular use [<i>AFLURIA TIV, FLUARIX TIV,</i> <i>FLUZONE TIV</i>] | 1 | 19+ | <u>23.22</u> 20.67 |
| 90657 | | Influenza virus vaccine, trivalent (IIV3), split virus, 0.25 mL dosage, for intramuscular use [<i>FLUZONE TIV</i>] | ± | 0-2 | 0.00 |
| 90658 | | Influenza virus vaccine, trivalent (IIV3), split virus, 0.5 mL dosage, for intramuscular use [<i>AFLURIA TIV, FLULAVAL TIV</i>] | 1 | <u>19+</u> 0-18 | <u>22.07</u> 0 |
| 90658 | HA | Influenza virus vaccine, trivalent (IIV3), split virus, 0.5 mL dosage, for intramuscular use [<i>AFLURIA TIV, FLUZONE TIV</i>] | ± | 19+ | 21.14 |
| 90662 | | Influenza virus vaccine (IIV), split virus, preservative free, enhanced immunogenicity via increased antigen content, for intramuscular use [<i>FLUZONE HIGH-DOSE</i>] | 1 | 18+ | <u>98.16</u> 83.49 |
| Influenza (LAIV3) | | | | | |
| 90660 | | Influenza virus vaccine, trivalent, live (LAIV3), for intranasal use [<i>FLUMIST TIV</i>] | 1 | 2-18 | 0.00 |
| 90660 | HA | Influenza virus vaccine, trivalent, live (LAIV3), for intranasal use [<i>FLUMIST TIV</i>] | 1 | 19+ | <u>29.71</u> 24.70 |
| Influenza (ccIV3) | | | | | |

| PRESCRIBED DRUGS IMMUNIZATION FEE SCHEDULE | | | | | |
|---|----|---|---|----------------------|-----------------------------|
| EFFECTIVE: JANUARY 1, 2026 2025 | | | | | |
| 90661 | | Influenza virus vaccine, trivalent (ccIV3), derived from cell cultures, subunit, antibiotic free, 0.5 mL dosage, for intramuscular use [FLUCELVAX TIV PF] | 1 | 0 - 18 | 0.00 |
| 90661 | HA | Influenza virus vaccine, trivalent (ccIV3), derived from cell cultures, subunit, antibiotic free, 0.5 mL dosage, for intramuscular use [FLUCELVAX TIV; FLUCELVAX TIV PF] | 1 | 19+ | 49.50 32.45 |
| Influenza (RIV3) | | | | | |
| 90673 | | Influenza virus vaccine, trivalent (RIV3), derived from recombinant DNA, hemagglutinin (HA) protein only, preservative and antibiotic free, for intramuscular use [FLUBLOK] | 1 | 18 | 98.16 83.49 |
| 90673 | HA | Influenza virus vaccine, trivalent (RIV3), derived from recombinant DNA, hemagglutinin (HA) protein only, preservative and antibiotic free, for intramuscular use [FLUBLOK] | 1 | 19+ | 98.16 83.49 |
| MEASLES, MUMPS, RUBELLA (MMR) | | | | | |
| MMR | | | | | |
| 90707 | | Measles, mumps and rubella virus vaccine (MMR), live, for subcutaneous use [M-M-R II; PRIORIX] | 1 | 0-18 | 0.00 |
| 90707 | HA | Measles, mumps and rubella virus vaccine (MMR), live, for subcutaneous use [M-M-R II; PRIORIX] | 1 | 19+ | 96.60 93.85 |
| MMR/VZV Combination | | | | | |
| 90710 | | Measles, mumps, rubella, and varicella vaccine (MMRV), live, for subcutaneous use [PROQUAD] | 1 | 4-12-1-12 | 0.00 |
| VARICELLA (VAR) | | | | | |
| 90716 | | Varicella virus vaccine (VAR), live, for subcutaneous use [VARIVAX] | 1 | 0-18 | 0.00 |
| 90716 | HA | Varicella virus vaccine (VAR), live, for subcutaneous use [VARIVAX] | 1 | 19+ | 192.12 183.00 |
| HEPATITIS A (HepA) | | | | | |
| 90632 | | Hepatitis A vaccine (HepA), adult dosage, for intramuscular use [VAQTA-ADULT; HAVRIX-ADULT] | 1 | 19+ 18+ | 84.94 82.10 |
| 90633 | | Hepatitis A vaccine (HepA), pediatric/adolescent dosage-2 dose schedule, for intramuscular use [VAQTA-PEDS; HAVRIX-PEDS] | 1 | 0-18 | 0.00 |
| HUMAN PAPILOMAVIRUS (HPV) | | | | | |
| 90651 | | Human Papillomavirus vaccine types 6, 11, 16, 18, 31, 33, 45, 52, 58, nonavalent (9vHPV), 2 or 3 dose schedule, for intramuscular use [GARDASIL 9] | 1 | 9 - 18 | 0.00 |
| 90651 | HA | Human Papillomavirus vaccine types 6, 11, 16, 18, 31, 33, 45, 52, 58, nonavalent (9vHPV), 2 or 3 dose schedule, for intramuscular use [GARDASIL 9] | 1 | 19 - 45 | 329.09 307.61 |
| MENINGOCOCCAL CONJUGATE (MenACWY) | | | | | |
| 90619 | | Meningococcal conjugate vaccine, serogroups A, C, W, Y, quadrivalent, tetanus toxoid carrier (MenACWY-TT), for intramuscular use [MenQuadfi] | 1 | 2-18 | 0.00 |
| 90619 | HA | Meningococcal conjugate vaccine, serogroups A, C, W, Y, quadrivalent, tetanus toxoid carrier (MenACWY-TT), for intramuscular use [MenQuadfi] | 1 | 19+ | 171.97 166.98 |
| 90734 | | Meningococcal conjugate vaccine, serogroups A, C, W, Y, quadrivalent, diphtheria toxoid carrier (MenACWY-D) or CRM197 carrier (MenACWY-CRM), for intramuscular use [MENVEO] | 1 | 0-18 | 0.00 |

| PRESCRIBED DRUGS IMMUNIZATION FEE SCHEDULE | | | | | |
|--|--------|---|----------|------------------------|------------------------------------|
| EFFECTIVE: JANUARY 1, 2026 2025 | | | | | |
| 90734 | HA | Meningococcal conjugate vaccine, serogroups A, C, W, Y, quadrivalent, diphtheria toxoid carrier (MenACWY-D) or CRM197 carrier (MenACWY-CRM), for intramuscular use [MENVEO] | 1 | 19+ | <u>166.75</u> 157.35 |
| MENINGOCOCCAL SEROGROUP B (MenB) | | | | | |
| 90620 | | Meningococcal recombinant protein and outer membrane vesicle vaccine, serogroup B (MenB-4C), 2 dose schedule, for intramuscular use [BEXSERO] | 1 | 10-18 | 0.00 |
| 90620 | HA | Meningococcal recombinant protein and outer membrane vesicle vaccine, serogroup B (MenB-4C), 2 dose schedule, for intramuscular use [BEXSERO] | 1 | 19+ | <u>237.13</u> 223.75 |
| 90621 | | Meningococcal recombinant lipoprotein vaccine, serogroup B (MenB-FHbp), 2 or 3 dose schedule, for intramuscular use [TRUMENBA] | 1 | 10-18 | 0.00 |
| 90621 | HA | Meningococcal recombinant lipoprotein vaccine, serogroup B (MenB-FHbp), 2 or 3 dose schedule, for intramuscular use [TRUMENBA] | 1 | 19+ | <u>207.32</u> 190.26 |
| MENINGOCOCCAL CONJUGATE (MenABCWY) | | | | | |
| 90623 | | Meningococcal pentavalent vaccine, conjugated Men A, C, W, Y-tetanus toxoid carrier, and Men B-FHbp, for intramuscular use [PENBRAYA] | 1 | 10-18 | 0.00 |
| 90623 | HA | Meningococcal pentavalent vaccine, conjugated Men A, C, W, Y-tetanus toxoid carrier, and Men B-FHbp, for intramuscular use [PENBRAYA] | 1 | 19+ | <u>237.65</u> 230.75 |
| ZOSTER RECOMBINANT (RZV) | | | | | |
| 90750 | | Zoster (shingles) vaccine (HZV), recombinant, subunit, adjuvanted, for intramuscular use [SHINGRIX] | 1 | 18+ | <u>215.51</u> 197.9 |
| RABIES | | | | | |
| 90375 | | Rabies immune globulin (RIG), human, for intramuscular and/or subcutaneous use [HyperRAB, HyperRAB S/D, KEDRAB] | 9 | | <u>279.95</u> 280.37 |
| 90376 | | Rabies immune globulin, heat treated (RIG-HT), human, for intramuscular and/or subcutaneous use [IMOGAM RABIES - HT] | 9 | | 479.72 |
| 90675 | | Rabies vaccine, intramuscular [IMOVAX; RABAVERT] | 1 | | <u>319.75</u> 327.78 |
| RESPIRATORY SYNCYTIAL VIRUS ADMINISTRATION CODES AND VACCINES | | | | | |
| 96380 | | Administration of Respiratory Syncytial Virus monoclonal antibody, seasonal dose, intramuscular, with counseling^ | 1 | 0-2 | 10.00 |
| 96381 | | Administration of Respiratory Syncytial Virus monoclonal antibody, seasonal dose, intramuscular^ | 1 | 0-2 | 10.00 |
| 90380 | | Respiratory Syncytial Virus monoclonal antibody, seasonal dose; 0.5ml dosage for IM use (BEYFORTUS)^ | 1 | 0-1 | 0.00 |
| 90381 | | Respiratory Syncytial Virus monoclonal antibody, seasonal dose; 1ml dosage for IM use (BEYFORTUS)^ | 1 | 0-1 | 0.00 |
| 90381 | | Respiratory Syncytial Virus monoclonal antibody, seasonal dose; 1ml dosage for IM use (BEYFORTUS)^ | 2 | 1-2 | 0.00 |
| <u>90382</u> | | <u>RESPIRATORY SYNCYTIAL VIRUS, MONOCLONAL ANTIBODY, SEASONAL DOSE, 0.7 ML, FOR INTRAMUSCULAR USE (ENFLONISIA)</u> | <u>1</u> | <u>0-1</u> | <u>0.00</u> |
| 90678 | HD | Respiratory Syncytial Virus vaccine, preF, subunit, Bivalent, for Intramuscular use (ABRYSVO) | 1 | 10-18 (PREGNANCY ONLY) | <u>306.80</u> 295.00 |
| 90678 | HA, HD | Respiratory Syncytial Virus vaccine, preF, subunit, Bivalent, for Intramuscular use (ABRYSVO) | 1 | 19-59 (PREGNANCY ONLY) | <u>306.80</u> 295.00 |

| PRESCRIBED DRUGS IMMUNIZATION FEE SCHEDULE | | | | | |
|--|----|---|--------------|-----------|-----------------------------|
| EFFECTIVE: JANUARY 1, 2026 2025 | | | | | |
| 90678 | HA | Respiratory Syncytial Virus vaccine, preF, subunit, Bivalent, for Intramuscular use (ABRYSVO) | 1 | 60+ | 306.80 295.00 |
| 90679 | | Respiratory Syncytial Virus vaccine, preF, Recombinant, subunit, Adjuvanted, for Intramuscular use (AREXVY) | 1 | 60+ | 294.00 306.35 |
| 90683 | | Respiratory Syncytial Virus vaccine, preF, subunit, Bivalent, for Intramuscular use (mRESVIA) | 1 | 60+ | 290.00 |
| COVID-19 ADMINISTRATION CODE & VACCINES | | | | | |
| 90480 | | Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, single dose (all manufacturers)* | 1 | ANY | 10.00 |
| 91304 | | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, 5 mcg/0.5 mL dosage, for intramuscular use [NUVAXOVID, 2025-2026 Formula NOVAVAX] | 1 | 12-18 | 0.00 |
| 91304 | HA | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, 5 mcg/0.5 mL dosage, for intramuscular use [NUVAXOVID, 2025-2026 Formula NOVAVAX] | 1 | 19+ | 191.92 141.70 |
| 91318 | | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, 3-mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use [Pfizer-BioNTech Covid-19 Vaccine] | ± | 6MO-4YRS | 0.00 |
| 91319 | | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, 10 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use [COMIRNATY, 2025-2026 Formula Pfizer-BioNTech COVID-19 Vaccine] | 1 | 5-11YRS | 0.00 |
| 91320 | | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use [COMIRNATY, 2025-2026 Formula - no freeze formulation] | 1 | 12-18 | 0.00 |
| 91320 | HA | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use [COMIRNATY, 2025-2026 Formula - no freeze formulation] | 1 | 19+ | 168.37 136.75 |
| 91321 | | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, 25 mcg/0.25 mL dosage, for intramuscular use [SPIKEVAX, 2025-2026 Formula Moderna COVID-19 Vaccine (US Only)] | 1 | 6MO-11YRS | 0.00 |
| 91322 | | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, 50 mcg/0.5 mL dosage, for intramuscular use [SPIKEVAX, 2025-2026 Formula] | 1 | 12-18 | 0.00 |
| 91322 | HA | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, 50 mcg/0.5 mL dosage, for intramuscular use [SPIKEVAX, 2025-2026 Formula] | 1 | 19+ | 161.65 141.80 |